An unidentified worker checks vials of insulin at the Novo Nordisk factory in Kalundborg, Denmark. A Kansas City-based researcher led a study published this week that found that the company’s new long-acting insulin cut hypoglycemic diabetic emergencies by 40 percent.
An unidentified worker checks vials of insulin at the Novo Nordisk factory in Kalundborg, Denmark. A Kansas City-based researcher led a study published this week that found that the company’s new long-acting insulin cut hypoglycemic diabetic emergencies by 40 percent. Novo Nordisk via Bloomberg News.
An unidentified worker checks vials of insulin at the Novo Nordisk factory in Kalundborg, Denmark. A Kansas City-based researcher led a study published this week that found that the company’s new long-acting insulin cut hypoglycemic diabetic emergencies by 40 percent. Novo Nordisk via Bloomberg News.

HCA Midwest researcher’s insulin study finds reductions in diabetic emergencies

June 13, 2017 12:18 PM